941PDAn investigator initiated, open label, randomized, controlled, multicentric study, to assess the safety and efficacy of nimotuzumab (BIOMAb-EGFR) concurrent with cisplatin and radiotherapy (RT) in histologically documented squamous cell carcinoma of the cervix
Ajaikumar, B.S., Swamy, K., Radheshyam, N., Patil, S., Shashidhara, H.P., Vishweshwara, M.S.A., Rao, N.K., Madhavi, Y., Ravi, N., Bilimagga, R., Rao, R., Pawar, D.Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx372.011
Date:
September, 2017
File:
PDF, 99 KB
english, 2017